These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 21706145

  • 1. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R.
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [Abstract] [Full Text] [Related]

  • 2. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
    Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R.
    Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046
    [Abstract] [Full Text] [Related]

  • 3. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M.
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [Abstract] [Full Text] [Related]

  • 4. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 5. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM.
    Drugs; 2012 Feb 12; 72(3):415-35. PubMed ID: 22316355
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.
    Haematologica; 2019 Nov 12; 104(11):2283-2291. PubMed ID: 30846500
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
    Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS, Wang YM, Nie K, Jun S.
    Blood; 2011 Jul 07; 118(1):28-36. PubMed ID: 21502541
    [Abstract] [Full Text] [Related]

  • 8. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.
    Br J Haematol; 2016 Jan 07; 172(2):262-73. PubMed ID: 26537623
    [Abstract] [Full Text] [Related]

  • 9. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M.
    Lancet; 2016 Jul 02; 388(10039):45-54. PubMed ID: 27103127
    [Abstract] [Full Text] [Related]

  • 10. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.
    J Clin Pharm Ther; 2014 Aug 02; 39(4):376-82. PubMed ID: 24702274
    [Abstract] [Full Text] [Related]

  • 11. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, Janssens A, Kozak T, Wadenvik H, Schoonen M, Belton L, Kreuzbauer G.
    Eur J Haematol; 2017 Feb 02; 98(2):112-120. PubMed ID: 27557853
    [Abstract] [Full Text] [Related]

  • 12. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.
    Blood; 2011 Oct 20; 118(16):4338-45. PubMed ID: 21832276
    [Abstract] [Full Text] [Related]

  • 13. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD, Despotovic J, Roy J, Grainger J, Cooper N, Beam D, Raj A, Maschan A, Kim J, Eisen M.
    Pediatr Blood Cancer; 2020 Nov 20; 67(11):e28630. PubMed ID: 32902132
    [Abstract] [Full Text] [Related]

  • 14. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
    Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP.
    Int J Hematol; 2009 Sep 20; 90(2):157-165. PubMed ID: 19543952
    [Abstract] [Full Text] [Related]

  • 15. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G.
    Eur J Haematol; 2015 Feb 20; 94(2):169-76. PubMed ID: 25039799
    [Abstract] [Full Text] [Related]

  • 16. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU, Newland A, McDonald V, Nandigam R, Mensah L, Leroy S, Seesaghur A, Patel H, Wetten S, Provan D.
    Eur J Haematol; 2019 May 20; 102(5):416-423. PubMed ID: 30758874
    [Abstract] [Full Text] [Related]

  • 17. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
    Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.
    Ann Hematol; 2016 Jun 20; 95(7):1077-87. PubMed ID: 27130310
    [Abstract] [Full Text] [Related]

  • 18. Romiplostim or standard of care in patients with immune thrombocytopenia.
    Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP.
    N Engl J Med; 2010 Nov 11; 363(20):1889-99. PubMed ID: 21067381
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B, Sninska Z, Tzvetkov N, Ivanushkin V, Björklöf K, Hippenmeyer J, Mihaylov G.
    Hematology; 2021 Dec 11; 26(1):497-502. PubMed ID: 34238136
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R.
    Am J Hematol; 2020 Jun 11; 95(6):643-651. PubMed ID: 32129511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.